Cargando…

Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase

BACKGROUND: Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome; MPS VI) is an autosomal recessive lysosomal storage disorder in which deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B; ARSB) leads to the storage of glycosaminoglycans (GAGs) in connective tissue. The genotype-pheno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brands, Marion M, Hoogeveen-Westerveld, Marianne, Kroos, Marian A, Nobel, Willemieke, Ruijter, George J, Özkan, Lale, Plug, Iris, Grinberg, Daniel, Vilageliu, Lluïsa, Halley, Dicky J, Ploeg, Ans T van der, Reuser, Arnold J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637222/ https://www.ncbi.nlm.nih.gov/pubmed/23557332 http://dx.doi.org/10.1186/1750-1172-8-51

Ejemplares similares

Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI
por: Harmatz, Paul R., et al.
Publicado: (2013)

Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease
por: van Gelder, Carin M., et al.
Publicado: (2014)

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase
por: El Dib, Regina P, et al.
Publicado: (2009)

Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series
por: Lin, Hsiang-Yu, et al.
Publicado: (2016)

Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme(®)) therapy
por: Koseoglu, Selim T., et al.
Publicado: (2008)

Antibody formation to enzyme therapy in classic infantile Pompe disease: implications of patient age
por: van Gelder, C, et al.
Publicado: (2013)

Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome): a case report
por: Andrade, Isadora, et al.
Publicado: (2022)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

A higher dose of enzyme therapy in patients with classic infantile Pompe disease seems to improve ventilator-free survival and motor function
por: van Gelder, C, et al.
Publicado: (2013)

The TSC1-TSC2 complex consists of multiple TSC1 and TSC2 subunits
por: Hoogeveen-Westerveld, Marianne, et al.
Publicado: (2012)

Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study
por: van Gelder, C. M., et al.
Publicado: (2016)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II
por: Catalano, Fabio, et al.
Publicado: (2023)

Impact of enzyme replacement therapy on survival in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Visual impairment in mucopolysaccharidosis VI
por: Magalhães, Augusto Monteiro, et al.
Publicado: (2023)

Identification of Regions Critical for the Integrity of the TSC1-TSC2-TBC1D7 Complex
por: Santiago Lima, Arthur Jorge, et al.
Publicado: (2014)

Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex
por: Mozaffari, Melika, et al.
Publicado: (2009)

Diagnostic and treatment strategies in mucopolysaccharidosis VI
por: Vairo, Filippo, et al.
Publicado: (2015)

SR proteins and the nonsense-mediated decay mechanism are involved in human GLB1 gene alternative splicing
por: Santamaria, Raül, et al.
Publicado: (2008)

Extension of the Pompe mutation database by linking disease‐associated variants to clinical severity
por: Niño, Monica Y., et al.
Publicado: (2019)

Mucopolysaccharidosis VI in cats – clarification regarding genetic testing
por: Lyons, Leslie A., et al.
Publicado: (2016)

Vertebral Tongue-Like Deformity in Mucopolysaccharidosis VI
por: Landen, Michiel, et al.
Publicado: (2021)

Epidemiology and Genetics of Mucopolysaccharidosis Type VI in Russia
por: Voskoboeva, Elena, et al.
Publicado: (2022)

Mucopolysaccharidosis Type VI, an Updated Overview of the Disease
por: D’Avanzo, Francesca, et al.
Publicado: (2021)

Mucopolysaccharidosis Type VI with Recurrent Chest Infection
por: Numan, Ashraf, et al.
Publicado: (2023)

Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype
por: Valstar, Marlies J., et al.
Publicado: (2010)

Sanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches
por: Benetó, Noelia, et al.
Publicado: (2020)

Craniosynostosis affects the majority of mucopolysaccharidosis patients and can contribute to increased intracranial pressure
por: Oussoren, Esmee, et al.
Publicado: (2018)

Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene
por: Tomanin, Rosella, et al.
Publicado: (2018)

Segmental and total uniparental isodisomy (UPiD) as a disease mechanism in autosomal recessive lysosomal disorders: evidence from SNP arrays
por: Labrijn-Marks, Ineke, et al.
Publicado: (2019)

Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up
por: Güngör, Deniz, et al.
Publicado: (2015)

Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study
por: Güngör, Deniz, et al.
Publicado: (2013)

Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment
por: Giugliani, Roberto, et al.
Publicado: (2010)

Hemifacial Spasm in Mucopolysaccharidosis Type VI (Maroteaux–Lamy Syndrome)
por: Karir, Aneesh, et al.
Publicado: (2018)

Analysis of Mucopolysaccharidosis Type VI through Integrative Functional Metabolomics
por: Tebani, Abdellah, et al.
Publicado: (2019)

EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome
por: Canals, Isaac, et al.
Publicado: (2015)

Orofacial abnormalities in mucopolysaccharidosis and mucolipidosis type II and III: A systematic review
por: de Bode, Chiel J., et al.
Publicado: (2022)

Enzyme replacement therapy and fatigue in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Prevalence of Anti–Adeno-Associated Virus Serotype 8 Neutralizing Antibodies and Arylsulfatase B Cross-Reactive Immunologic Material in Mucopolysaccharidosis VI Patient Candidates for a Gene Therapy Trial
por: Ferla, Rita, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8llburbm29gkulalenvjurs7ek